How Attruby (acoramidis) Works – Compliance Alert

Lower Risk

This HCP Educational video is within acceptable compliance thresholds.

Analysis of this 241s HCP Educational video identified 2 enforcement patterns, primarily Efficacy. Patterns span Efficacy — “Comparative Claims” identified at 113.8s, previously cited in NEXLIZET, COBENFY.

Video Timeline

Risk disclosure: 6.6s – 147.0s (140.4s of 241.2s total — 58.2% of ad)

Risk Window

0s60s121s181s241s

No visual distractions detected

Risk Window?

Patterns Detected (2)

Each pattern below is a known FDA enforcement concern, identified by matching this ad against 14 violation types from 34 FDA warning letters

Pattern	Dimension	Score	Evidence	CFR
Comparative Claims Claims suggesting superiority without adequate supporting data	Efficacy	87	3 clips	21 CFR 202.1(e)(5)	▶
FDA Concern: Advertisements cannot be false or misleading in any particular Previously cited: NEXLIZET, COBENFY
Dramatic Before/After Before/after visuals that may overstate treatment outcomes	Efficacy	87		21 CFR 202.1(e)(5)	▶
FDA Concern: Advertisements cannot be false or misleading in any particular Previously cited: TURALIO, TREMFYA

Compliance Alert: How Attruby (acoramidis) Works

Recommendations